News
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the U.S. Food and Drug Administration (U.S. FDA) has approved Jobevnetm (bevacizumab-nwgd), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback